Ocriplasmin for vitreoretinal diseases.

Article Details

Citation

Tsui I, Pan CK, Rahimy E, Schwartz SD

Ocriplasmin for vitreoretinal diseases.

J Biomed Biotechnol. 2012;2012:354979. doi: 10.1155/2012/354979. Epub 2012 Oct 14.

PubMed ID
23193358 [ View in PubMed
]
Abstract

Fibronectin and laminin are clinically relevant plasmin receptors in the eye. Located at the vitreoretinal interface, they are cleaved by ocriplasmin (Microplasmin, ThromboGenics, Iselin, NJ), a novel ophthalmic medication. A series of clinical trials to study ocriplasmin for the treatment of vitreoretinal diseases such as vitreomacular traction, macular hole, and exudative age-related macular degeneration are underway. The results are promising and may impact patient care.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
OcriplasminFibronectinProteinHumans
Yes
Cleavage
Details